Berlex’ Yaz User Fee Date Extended
This article was originally published in The Pink Sheet Daily
FDA has extended the user fee date for Berlex' oral contraceptive Yaz by three months, parent company Schering AG said Dec. 9
You may also be interested in...
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.